Lin Jia-Xin, Sun Hao, Peng Ying-Long, Xie Zhi, Liu Si-Yang Maggie, Wu Yi-Long
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Transl Lung Cancer Res. 2025 Apr 30;14(4):1482-1495. doi: 10.21037/tlcr-24-866. Epub 2025 Apr 17.
BACKGROUND AND OBJECTIVE: The mesenchymal-epithelial transition factor (MET) proto-oncogene plays an important role in the development of non-small cell lung cancer (NSCLC). MET tyrosine kinase inhibitors (TKIs) have shown promising antitumor activity in patients with NSCLC harboring MET alterations. Peripheral edema (PE), the most common adverse event of MET TKIs, has received increasing attention from clinicians. The aim of this review is to describe the incidence, potential molecular mechanisms, diagnosis, and management of MET TKI-induced PE, to increase the recognition and standardize the management of PE. METHODS: We conducted a comprehensive literature search across PubMed, Wanfang Med Online, China National Knowledge Infrastructure (CNKI), and the oncology conferences websites for related studies published between 2000 and 2023. Of the 491 titles screened, we identified 80 research articles fitting the inclusion criteria and a comprehensive literature review was conducted. The review incorporated patient conditions, comprehensive examinations, and clinical experiences to propose a standardized management framework. KEY CONTENT AND FINDINGS: The review focused on the incidence of MET TKI-induced PE, its potential molecular mechanisms, diagnostic criteria, and management strategies. The etiology of edema is complex in cancer patients; however, it may involve treatment-related increases in vascular permeability, impacts on renal function, and hypoalbuminemia. Based on the literature review, a diagnostic and comprehensive management approach for MET TKI-induced PE is proposed, which includes prevention strategies, non-pharmacological treatments, pharmacological interventions, and dosage adjustments related to MET TKIs. CONCLUSIONS: In this review, we propose a diagnostic and comprehensive management approach for MET TKI-induced PE. By standardizing management, clinicians can enhance patient care for those treated with MET TKIs, facilitating earlier detection of PE, reducing patient suffering, and improving treatment adherence and outcomes.
背景与目的：间充质-上皮转化因子（MET）原癌基因在非小细胞肺癌（NSCLC）的发生发展中起重要作用。MET酪氨酸激酶抑制剂（TKIs）在携带MET改变的NSCLC患者中显示出有前景的抗肿瘤活性。外周水肿（PE）是MET TKIs最常见的不良事件，已受到临床医生越来越多的关注。本综述的目的是描述MET TKI诱导的PE的发生率、潜在分子机制、诊断和管理，以提高对PE的认识并规范其管理。 方法：我们在PubMed、万方医学网、中国知网和肿瘤学会议网站上进行了全面的文献检索，以查找2000年至2023年期间发表的相关研究。在筛选的491篇标题中，我们确定了80篇符合纳入标准的研究文章，并进行了全面的文献综述。该综述结合患者情况、综合检查和临床经验，提出了一个标准化的管理框架。 关键内容与发现：该综述重点关注MET TKI诱导的PE的发生率、潜在分子机制、诊断标准和管理策略。癌症患者水肿的病因复杂；然而，它可能涉及与治疗相关的血管通透性增加、对肾功能的影响和低白蛋白血症。基于文献综述，提出了一种针对MET TKI诱导的PE的诊断和综合管理方法，包括预防策略、非药物治疗、药物干预以及与MET TKIs相关的剂量调整。 结论：在本综述中，我们提出了一种针对MET TKI诱导的PE的诊断和综合管理方法。通过规范管理，临床医生可以加强对接受MET TKIs治疗患者的护理，促进PE的早期发现，减轻患者痛苦，并提高治疗依从性和治疗效果。
Transl Lung Cancer Res. 2024-4-29
Cancers (Basel). 2023-9-28
N Engl J Med. 2023-7-13
Zhonghua Zhong Liu Za Zhi. 2023-4-23
Clin Kidney J. 2022-8-1
Zotero 插件